How should a patient with suspected neurofibromatosis be evaluated and managed, including genetic testing, imaging, and treatment options?

Neurofibromatosis Type 1: Evaluation and Management

Adults with suspected NF1 should be referred to a specialized NF1 clinic for coordinated care, as this approach reduces the 8-15 year reduction in life expectancy primarily caused by malignant peripheral nerve sheath tumors (MPNST) and breast cancer 1.

Diagnostic Evaluation

Clinical Diagnosis

The diagnosis can be established clinically using revised diagnostic criteria 2. Key features include:

• Café-au-lait macules: 99% of patients have ≥6 spots by age 12 months
• Cutaneous and plexiform neurofibromas
• Axillary/inguinal freckling
• Optic pathway gliomas
• Lisch nodules (iris hamartomas)
• Distinctive osseous lesions
• First-degree relative with NF1

Genetic Testing

Genetic testing can quickly establish diagnosis and relieve anxiety, though this is less critical in adults than children 1. Sequence the NF1 gene to identify the pathogenic variant, which aids genetic counseling 3. If sequencing fails to reveal a variant, also sequence tumor tissue 3.

Common pitfall: The NF1 phenotype severity varies dramatically even within families, so genetic testing provides limited prognostic value 1.

Initial Imaging Assessment

Baseline Studies

At diagnosis, obtain 1, 3:

• Whole-body MRI to establish baseline tumor burden
• Baseline MRI of known or suspected plexiform neurofibromas (non-superficial)
• Consider DEXA scan based on age and clinical presentation (vitamin D deficiency and bone complications are common)

Women-Specific Screening

For women with NF1 1:

• Annual mammography starting at age 30 (not 40-50 as in general population)
• Consider annual breast MRI with contrast between ages 30-50

Important caveat: These breast screening recommendations are based on expert opinion by analogy to other intermediate-risk syndromes, not NF1-specific evidence 1.

Surveillance Protocol

Annual Evaluation Components 1

History - Screen for life-threatening complications:

1. MPNST warning signs: Progressive severe pain, changes in tumor volume, new unexplained neurologic symptoms
2. Pheochromocytoma: Diaphoresis, palpitations, hypertension
3. Neuropathy symptoms
4. Depression and psychiatric symptoms (highly prevalent)
5. Chronic pain and pruritus
6. Fingertip pain (glomus tumors)

Physical Examination:

• Blood pressure measurement (essential hypertension vs. pheochromocytoma)
• Scoliosis screening with Adam's forward bend test

Laboratory Testing:

• Serum vitamin D levels with supplementation as needed 1
• Serum metanephrines (for pheochromocytoma screening) 3
• Sex hormone status 3

Critical Mortality Risks

Malignant Peripheral Nerve Sheath Tumor (MPNST)

MPNST is the leading cause of death in NF1, with cumulative risks of 8.5% by age 30,12.3% by age 50, and 15.8% by age 85 1. These tumors are clinically aggressive with early metastasis and standardized mortality ratio >2,000 1.

Red flags requiring immediate evaluation:

• Progressive, severe pain in existing neurofibroma
• Rapid increase in tumor volume
• New neurologic deficits

Breast Cancer

Women with NF1 have significantly increased breast cancer risk at younger ages, necessitating enhanced surveillance starting at age 30 1, 4.

Treatment Approach

Tumor Management

Surgery remains the primary treatment for symptomatic tumors 5. For specific tumor types:

• Plexiform neurofibromas: Consider MEK inhibitors (off-label) for progressive symptomatic lesions 6
• MPNST: Aggressive surgical resection when feasible; outcomes have improved in the past decade 1

Symptom Management

• Migraine, seizures, sleep disorders: Treat as in non-NF1 population 1
• NF1 neuropathy: Medication, physical therapy, surgery for compressive tumors 1
• Glomus tumors: Surgical excision is curative but diagnosis is often delayed; MRI helpful 1
• Chronic pain: Screen with pain-interference scales; refer to multidisciplinary pain clinic using both pharmacologic and non-pharmacologic approaches 1

Critical pitfall: Not all pain in NF1 is NF1-related—common causes (lower back pain, tension headaches) remain common 1.

Pregnancy Considerations

Pregnant women with NF1 should be referred to high-risk obstetrics 1. NF1 is associated with increased maternal morbidity including gestational hypertension, preeclampsia, intrauterine growth restriction, and preterm labor, though not increased mortality 1.

• 55-60% of women report growth of neurofibromas during pregnancy; 30% observe postpartum regression 1
• Neuraxial imaging before epidural anesthesia is probably not needed unless specific concerns exist 1
• Counsel that offspring recurrence risk is 50% (autosomal dominant) 1
• Preimplantation genetic diagnosis and prenatal diagnosis are available 1

Specialized Care Coordination

Although primary care physicians can manage many NF1 issues, evaluation by and care coordination with a specialized NF1 clinic is strongly encouraged 1. The Children's Tumor Foundation sponsors the NF Clinic Network nationwide 1. Specialized clinics provide:

• Access to emerging targeted therapies
• Multidisciplinary expertise for complex manifestations
• Research study opportunities
• Comprehensive psychosocial support

Quality of Life Considerations

Beyond tumor surveillance, address 1:

• Cognitive and behavioral impairments (learning disabilities, ADHD, social communication difficulties) 4
• Psychiatric diagnoses (depression, anxiety)
• Chronic pain and pruritus
• Cosmetic concerns from cutaneous neurofibromas
• Skeletal deformities and cardiovascular abnormalities 4

Patient education is paramount: Sensitize patients to warning signs while reassuring them that most symptoms have common explanations (most hypertension is essential, most back pain is not MPNST, most headaches are not tumor-related) 1.